Works matching IS 00071048 AND DT 2014 AND VI 164 AND IP 2

Results: 24
    1
    2
    3

    Measuring cereblon as a biomarker of response or resistance to lenalidomide and pomalidomide requires use of standardized reagents and understanding of gene complexity.

    Published in:
    British Journal of Haematology, 2014, v. 164, n. 2, p. 233, doi. 10.1111/bjh.12622
    By:
    • Gandhi, Anita K.;
    • Mendy, Derek;
    • Waldman, Michelle;
    • Chen, Gengxin;
    • Rychak, Emily;
    • Miller, Karen;
    • Gaidarova, Svetlana;
    • Ren, Yan;
    • Wang, Maria;
    • Breider, Michael;
    • Carmel, Gilles;
    • Mahmoudi, Afshin;
    • Jackson, Pilgrim;
    • Abbasian, Mahan;
    • Cathers, Brian E.;
    • Schafer, Peter H.;
    • Daniel, Tom O.;
    • Lopez‐Girona, Antonia;
    • Thakurta, Anjan;
    • Chopra, Rajesh
    Publication type:
    Article
    4
    5
    6
    7
    8
    9
    10
    11

    Copper deficiency anaemia.

    Published in:
    British Journal of Haematology, 2014, v. 164, n. 2, p. 161, doi. 10.1111/bjh.12577
    By:
    • Kobayashi, Yujin;
    • Hatta, Yoshihiro
    Publication type:
    Article
    12
    13
    14
    15

    Imatinib 800 mg daily induces deeper molecular responses than imatinib 400 mg daily: results of SWOG S0325, an intergroup randomized PHASE II trial in newly diagnosed chronic phase chronic myeloid leukaemia.

    Published in:
    British Journal of Haematology, 2014, v. 164, n. 2, p. 223, doi. 10.1111/bjh.12618
    By:
    • Deininger, Michael W.;
    • Kopecky, Kenneth J.;
    • Radich, Jerald P.;
    • Kamel‐Reid, Suzanne;
    • Stock, Wendy;
    • Paietta, Elisabeth;
    • Emanuel, Peter D.;
    • Tallman, Martin;
    • Wadleigh, Martha;
    • Larson, Richard A.;
    • Lipton, Jeffrey H.;
    • Slovak, Marilyn L.;
    • Appelbaum, Frederick R.;
    • Druker, Brian J.
    Publication type:
    Article
    16
    17
    18

    Phase IA/ II, multicentre, open-label study of the CD40 antagonistic monoclonal antibody lucatumumab in adult patients with advanced non- Hodgkin or Hodgkin lymphoma.

    Published in:
    British Journal of Haematology, 2014, v. 164, n. 2, p. 258, doi. 10.1111/bjh.12630
    By:
    • Fanale, Michelle;
    • Assouline, Sarit;
    • Kuruvilla, John;
    • Solal‐Céligny, Philippe;
    • Heo, Dae S.;
    • Verhoef, Gregor;
    • Corradini, Paolo;
    • Abramson, Jeremy S.;
    • Offner, Fritz;
    • Engert, Andreas;
    • Dyer, Martin J. S.;
    • Carreon, Daniel;
    • Ewald, Brett;
    • Baeck, Johan;
    • Younes, Anas;
    • Freedman, Arnold S.
    Publication type:
    Article
    19

    Long-term molecular remission with persistence of BCR- ABL1-specific cytotoxic T cells following imatinib withdrawal in an elderly patient with Philadelphia-positive ALL.

    Published in:
    British Journal of Haematology, 2014, v. 164, n. 2, p. 299, doi. 10.1111/bjh.12612
    By:
    • Riva, Giovanni;
    • Luppi, Mario;
    • Lagreca, Ivana;
    • Barozzi, Patrizia;
    • Quadrelli, Chiara;
    • Vallerini, Daniela;
    • Zanetti, Eleonora;
    • Basso, Sabrina;
    • Forghieri, Fabio;
    • Morselli, Monica;
    • Maccaferri, Monica;
    • Paolini, Ambra;
    • Fantuzzi, Valeria;
    • Messerotti, Andrea;
    • Maffei, Rossana;
    • Iacobucci, Ilaria;
    • Martinelli, Giovanni;
    • Marasca, Roberto;
    • Narni, Franco;
    • Comoli, Patrizia
    Publication type:
    Article
    20
    21
    22
    23
    24